Practices that order gloves by the case have likely already noticed the difference on their invoices. As of January 2026, tariffs on Chinese-origin medical-grade nitrile gloves reached their highest level in the industry's history, and the ripple effects are reaching every dental and medical office that relies on a steady, affordable glove supply.
What Changed
US tariffs on Chinese-origin medical-grade nitrile gloves reached 100% in January 2026, creating the highest industry price floor in history and affecting all supply origins via spillover effects. This escalation didn't happen overnight — the 100% Section 301 duty took effect January 1, 2026, doubling from the 50% rate that was in effect during 2025. Before that, the rate had sat at just 7.5% for years, so the increase represents a dramatic shift in cost structure for any office sourcing gloves from China.
Why It's Not Just a China Problem
Many offices assumed switching suppliers to Malaysia, Vietnam, or Thailand would sidestep the issue entirely. That's only partly true. Since China also dominates the upstream supply of nitrile-butadiene rubber (NBR), the raw material used to manufacture nitrile gloves, even gloves made in other countries face indirect cost pressure. On top of that, Malaysian-sourced gloves face a lower but still meaningful 19% tariff, reduced from an initial 25% rate after bilateral negotiations.
There's also a capacity issue building behind the scenes. As buyers redirect orders away from Chinese manufacturers, many labs assumed they could simply switch to Malaysian- or Vietnamese-origin gloves to avoid the impact of the China tariff — that assumption is partially correct and partially wrong. Non-China suppliers are absorbing a surge in demand they weren't necessarily built to handle at scale, which can translate into longer lead times even where tariffs are lower.
What This Means for Procurement
For dental practices, oral surgery centers, and medical offices, glove spend is one of the largest recurring PPE line items in the budget. A few practical considerations for the months ahead:
- Know your origin. Ask suppliers directly where gloves are manufactured — country of origin is now the single biggest driver of per-box cost.
- Diversify, but verify. Sourcing from multiple countries can reduce exposure to any one tariff schedule, but confirm actual manufacturing location rather than assuming a supplier's stated origin is unaffected.
- Avoid panic stockpiling. Gloves have a finite shelf life, and over-ordering in response to price anxiety can create its own cash flow and storage problems.
- Budget in advance. Build expected price increases into quarterly supply budgets now rather than reacting after invoices arrive.
The Bigger Picture
Glove pricing pressure is layering on top of other supply chain strain already being tracked by regulators. The FDA's Medical Device Shortages List initially identified more than 20 different medical devices for which limited supplies were available, including a variety of ventilators, specimen collection systems, and personal protective equipment; the updated list now covers a narrower set of six device categories — a reminder that supply availability across healthcare products remains an evolving situation worth monitoring, not a one-time event.
For practices, the takeaway is straightforward: glove costs are unlikely to return to pre-2025 levels in the near term. Treating glove procurement as a strategic, ongoing budget item — rather than a routine reorder — will help practices avoid surprises as 2026 progresses.